vimarsana.com

Latest Breaking News On - Cordlife group limited - Page 6 : vimarsana.com

Cord Blood Banking Market Is Booming Worldwide | China Cord Blood Corporation, Cord Blood America

Researchers conduct first-in-man clinical trial for new stem cell technology

Institutes and centres under the SingHealth Duke-NUS Academic Medical Centre (AMC) are joining hands together with Singapore's first private cord blood bank, Cordlife Group Limited (Cordlife), to test a novel technology that expands the number of blood-forming stem cells from stored umbilical cord blood (UCB) in a first-in-man study in Singapore.

SingHealth Duke-NUS Academic Medical Centre and Cordlife partner to advance stem cell technology to first-in-man clinical trial in Singapore

SingHealth Duke-NUS Academic Medical Centre and Cordlife partner to advance stem cell technology to first-in-man clinical trial in Singapore
asiaresearchnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaresearchnews.com Daily Mail and Mail on Sunday newspapers.

First-in-man clinical trial in S pore for stem cell technology by SingHealth Duke-NUS AMC, Cordlife

 E-Mail IMAGE: Upon collection after the delivery of a baby, cord blood is processed to extract stem cells and to prepare it for long-term cryopreservation view more  Credit: Cordlife Group Limited SINGAPORE, 11 May 2021 - Institutes and centres under the SingHealth Duke-NUS Academic Medical Centre (AMC) are joining hands together with Singapore s first private cord blood bank, Cordlife Group Limited (Cordlife), to test a novel technology that expands the number of blood-forming stem cells from stored umbilical cord blood (UCB) in a first-in-man study in Singapore. This is the first time a home-grown UCB cell therapy is being tested on humans. The technology has the potential to increase treatment options for patients suffering from blood cancers or blood-related conditions.

Cordlife launches OptiQ: A first-of-its-kind corneal lenticule banking service in Singapore

Source: Media Outreach SINGAPORE – Media OutReach – 3 March 2021 – Cordlife Group Limited, a consumer healthcare company announced today that the Ministry of Health has issued a license permitting the Company to launch OptiQ, a corneal lenticule banking service in Singapore. Cordlife is the first company in Asia to let patients undergoing refractive eye surgery using lenticule extraction method (e.g. SMILE) for myopia or astigmatism to  cryopreserve their corneal lenticules for potential treatment of presbyopia and other ocular conditions in the future. The technology behind OptiQ was invented by Professors Donald Tan and Jodhbir Mehta from Singapore Eye Research Institute (“SERI”), the research arm of Singapore National Eye Centre (“SNEC”).

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.